AG-Telmisartan tablet: Overweight & Underweight tablets
Brand(s)
Last updated
Summary
Product
AG-Telmisartan 40 mg & 80 tablet
Issue
Health products - Product quality
What to do
Consult your health care professional if you have any health concerns.
Affected products
| Brand | Product Name | Market Authorization | Dosage Form | Strength | Lot numbers |
|---|---|---|---|---|---|
| Angita | AG-Telmisartan 40 mg tablet | DIN 02484536 | Tablet | Telmisartan 40 mg | EG23AGI001, EG23AGI002, EG23AGI003, EG23AGD001, EG23AGD002, EG23AGD003 |
| Angita | AG-Telmisartan 80 mg tablet | DIN 02484544 | Tablet | Telmisartan 80 mg | EG22AGE002, EG23AGE001, EG23AGE002, EG23AGE004, EG23AGE005, EG23AGJ001, EG23AGJ002, EG23AGJ003 |
Issue
Affected lots may contain overweight or underweight tablets.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
ANGITA PHARMA INC.
1310 Rue Nobel,
Boucherville, QC J4B 5H3
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type II
Identification number
RA-76021
Get notified
Receive emails about new and updated recall and safety alerts.